This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

The ESC Council on Hypertension has released a statement, strongly recommending to continue treatment of ACEi and ARBs in times of the COVID-19 pandemic, as evidence for harmful effects of these drugs in context of COVID-19 is lacking.

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Bulgarian.

Sex-specific analysis of BP trajectories using data of >32,000 individuals indicates that BP elevation during life span increased faster in women than in men, starting at 30 years.

Download the Serbian version of the EPCCS Practical Guidance on Hypertension Management

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Czech.

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Czech.

A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.

A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Slovak.

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Ukrainian.

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Greek.